Comorbidities, medication and in-hospital outcomes according to myocardial injury
| All (N=498) | Myocardial injury (N=215) | No myocardial injury (N=283) | P value | |
| Comorbidities | ||||
| Cardiovascular disease | 319 (64.1%) | 164 (76.3%) | 155 (54.8%) | <0.001 |
| Diabetes | 200 (40.2%) | 96 (44.7%) | 104 (36.7%) | 0.08 |
| Hypertension | 266 (53.4%) | 138 (64.2%) | 128 (45.2%) | <0.001 |
| Dyslipidaemia | 158 (31.7%) | 66 (30.7%) | 92 (32.5%) | 0.698 |
| COPD | 34 (6.8%) | 15 (7.0%) | 19 (6.7%) | 0.908 |
| Asthma | 45 (9.0%) | 18 (8.4%) | 27 (9.5%) | 0.753 |
| Chronic Kidney Disease | 98 (19.7%) | 73 (34.0%) | 25 (8.8%) | <0.001 |
| ESRF on Dialysis | 37 (7.4%) | 35 (16.3%) | 2 (0.7%) | <0.001 |
| Coronary artery disease | 69 (13.9%) | 40 (18.6%) | 29 (10.2%) | 0.009 |
| Previous MI | 45 (9.0%) | 30 (14.0%) | 15 (5.3%) | 0.001 |
| Previous CABG | 11 (2.2%) | 5 (2.3%) | 6 (2.1%) | 0.877 |
| Atrial fibrillation | 65 (13.1%) | 41 (19.1%) | 24 (8.5%) | 0.001 |
| Previous PCI | 27 (5.4%) | 17 (7.9%) | 10 (3.5%) | 0.044 |
| Previous CVA | 59 (11.8%) | 31 (14.4%) | 28 (9.9%) | 0.126 |
| Medications | ||||
| ARB | 52 (10.4%) | 31 (14.4%) | 21 (7.4%) | 0.017 |
| ACEi | 100 (20.1%) | 52 (24.2%) | 48 (17.0%) | 0.055 |
| Outcomes | ||||
| Admission to ICU | 73 (16.7%) | 40 (18.6%) | 33 (11.7%) | 0.04 |
|  Intubation | 58 (11.6%) | 30 (14.0%) | 28 (9.9%) | 0.352 |
| Renal replacement therapy | 25 (5.0%) | 23 (10.7%) | 2 (0.7%) | <0.001 |
| Stroke | 8 (1.6%) | 4 (1.9%) | 4 (1.4%) | 0.731 |
| Death | 154 (30.9%) | 102 (47.4%) | 52 (18.4%) | <0.001 |
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; ESRF, end-stage renal failure; ICU, intensive care unit; MI, myocardial infarction; PCI, percutaneous coronary intervention.